STRO
Sutro Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.07
−2.29%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 45.7M | 102.5M | 62.0M | 153.7M | 67.8M |
| Cost of Revenue | 1.3M | 7.3M | 7.2M | 6.8M | 8.3M |
| Gross Profit | 44.4M | 95.2M | 54.8M | 146.9M | 59.5M |
| Operating Expenses | |||||
| R&D Expense | 144.7M | 166.4M | 252.0M | 180.4M | 137.2M |
| SG&A Expense | 32.8M | 41.0M | 48.5M | 62.6M | 59.5M |
| General & Admin Expense | 32.8M | 41.0M | 48.5M | 62.6M | 59.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 8.5M | (7.3M) | (7.2M) | (6.8M) | (8.3M) |
| Total Operating Expenses | 186.0M | 200.1M | 293.3M | 236.2M | 188.4M |
| Cost and Expenses | 187.3M | 207.4M | 300.5M | 243.0M | 196.7M |
| Operating Income (EBIT) | (141.6M) | (105.0M) | (238.5M) | (89.3M) | (128.9M) |
| Non-Operating | |||||
| Interest Income | 6.9M | 9.3M | 44.4M | 14.5M | 3.5M |
| Interest Expense | 40.1M | 38.2M | 31.1M | 23.8M | 3.3M |
| Net Interest Income | (33.2M) | (29.0M) | 13.4M | (9.2M) | 109.0K |
| Other Non-Op Income/Expense | (39.1M) | (86.2M) | 13.4M | 677.0K | 12.2M |
| Non-Operating Income (excl Interest) | (951.0K) | 48.0M | (50.8M) | (14.5M) | (15.6M) |
| EBT (Pre-Tax Income) | (180.7M) | (191.2M) | (225.1M) | (88.6M) | (116.7M) |
| Income Tax Expense | (96.0K) | (93.0K) | 2.4M | 18.2M | 2.5M |
| Bottom Line | |||||
| Net Income | (180.6M) | (191.1M) | (227.5M) | (106.8M) | (119.2M) |
| Earnings from Cont. Ops | (180.6M) | (191.1M) | (227.5M) | (106.8M) | (119.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (180.6M) | (191.1M) | (227.5M) | (106.8M) | (119.2M) |
| Per Share | |||||
| Basic EPS | ($17.42) | ($22.49) | ($29.60) | ($17.80) | ($23.50) |
| Diluted EPS | ($17.42) | ($22.49) | ($29.60) | ($17.80) | ($23.50) |
| Revenue Per Share | $2.76 | $12.06 | $8.08 | $25.55 | $13.36 |
| Shares | |||||
| Basic Shares Outstanding | 16.6M | 8.5M | 7.7M | 6.0M | 5.1M |
| Diluted Shares Outstanding | 16.6M | 8.5M | 7.7M | 6.0M | 5.1M |
| Profitability Metrics | |||||
| EBITDA | (134.6M) | (145.6M) | (180.5M) | (67.9M) | (105.1M) |
| D&A | 6.1M | 7.3M | 7.2M | 6.8M | 8.3M |
| EBIT | (140.7M) | (153.0M) | (187.7M) | (74.7M) | (113.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026